These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
564 related articles for article (PubMed ID: 28442293)
1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Gutiérrez-Gutiérrez B; Salamanca E; de Cueto M; Hsueh PR; Viale P; Paño-Pardo JR; Venditti M; Tumbarello M; Daikos G; Cantón R; Doi Y; Tuon FF; Karaiskos I; Pérez-Nadales E; Schwaber MJ; Azap ÖK; Souli M; Roilides E; Pournaras S; Akova M; Pérez F; Bermejo J; Oliver A; Almela M; Lowman W; Almirante B; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J; Lancet Infect Dis; 2017 Jul; 17(7):726-734. PubMed ID: 28442293 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection. Medeiros GS; Rigatto MH; Falci DR; Zavascki AP Int J Antimicrob Agents; 2019 Feb; 53(2):152-157. PubMed ID: 30722960 [TBL] [Abstract][Full Text] [Related]
3. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793 [TBL] [Abstract][Full Text] [Related]
4. Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing Klebsiella pneumoniae. Falcone M; Bassetti M; Tiseo G; Giordano C; Nencini E; Russo A; Graziano E; Tagliaferri E; Leonildi A; Barnini S; Farcomeni A; Menichetti F Crit Care; 2020 Jan; 24(1):29. PubMed ID: 32000834 [TBL] [Abstract][Full Text] [Related]
5. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Tumbarello M; Viale P; Viscoli C; Trecarichi EM; Tumietto F; Marchese A; Spanu T; Ambretti S; Ginocchio F; Cristini F; Losito AR; Tedeschi S; Cauda R; Bassetti M Clin Infect Dis; 2012 Oct; 55(7):943-50. PubMed ID: 22752516 [TBL] [Abstract][Full Text] [Related]
6. Treatment Outcome of Bacteremia Due to Non-Carbapenemase-producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia: Role of Carbapenem Combination Therapy. Lee NY; Tsai CS; Syue LS; Chen PL; Li CW; Li MC; Ko WC Clin Ther; 2020 Mar; 42(3):e33-e44. PubMed ID: 32061374 [TBL] [Abstract][Full Text] [Related]
7. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Mouloudi E; Protonotariou E; Zagorianou A; Iosifidis E; Karapanagiotou A; Giasnetsova T; Tsioka A; Roilides E; Sofianou D; Gritsi-Gerogianni N Infect Control Hosp Epidemiol; 2010 Dec; 31(12):1250-6. PubMed ID: 20973725 [TBL] [Abstract][Full Text] [Related]
8. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia. Seo H; Lee SC; Chung H; Ra SH; Sung H; Kim MN; Jung J; Kim MJ; Kim SH; Lee SO; Choi SH; Kim YS; Woo JH; Chong YP Int J Antimicrob Agents; 2020 Oct; 56(4):106126. PubMed ID: 32755654 [TBL] [Abstract][Full Text] [Related]
9. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. Gutiérrez-Gutiérrez B; Salamanca E; de Cueto M; Hsueh PR; Viale P; Paño-Pardo JR; Venditti M; Tumbarello M; Daikos G; Pintado V; Doi Y; Tuon FF; Karaiskos I; Machuca I; Schwaber MJ; Azap ÖK; Souli M; Roilides E; Pournaras S; Akova M; Pérez F; Bermejo J; Oliver A; Almela M; Lowman W; Almirante B; Bonomo RA; Carmeli Y; Paterson DL; Pascual A; Rodríguez-Baño J; Mayo Clin Proc; 2016 Oct; 91(10):1362-1371. PubMed ID: 27712635 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of short- versus prolonged-courses of antimicrobial therapy for carbapenem-resistant Klebsiella pneumoniae bloodstream infections: A propensity score-matched cohort study. You TY; Lo CL; Tsai WC; Jan HE; Ko WC; Lee NY J Microbiol Immunol Infect; 2024 Aug; 57(4):594-600. PubMed ID: 38849216 [TBL] [Abstract][Full Text] [Related]
11. Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections. Gomez-Simmonds A; Nelson B; Eiras DP; Loo A; Jenkins SG; Whittier S; Calfee DP; Satlin MJ; Kubin CJ; Furuya EY Antimicrob Agents Chemother; 2016 Jun; 60(6):3601-7. PubMed ID: 27044555 [TBL] [Abstract][Full Text] [Related]
12. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: Analysis of 50 cases. Tofas P; Skiada A; Angelopoulou M; Sipsas N; Pavlopoulou I; Tsaousi S; Pagoni M; Kotsopoulou M; Perlorentzou S; Antoniadou A; Pirounaki M; Skoutelis A; Daikos GL Int J Antimicrob Agents; 2016 Apr; 47(4):335-9. PubMed ID: 27005460 [TBL] [Abstract][Full Text] [Related]
13. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems. Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247 [TBL] [Abstract][Full Text] [Related]
14. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660 [TBL] [Abstract][Full Text] [Related]
15. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. Giannella M; Trecarichi EM; Giacobbe DR; De Rosa FG; Bassetti M; Bartoloni A; Bartoletti M; Losito AR; Del Bono V; Corcione S; Tedeschi S; Raffaelli F; Saffioti C; Spanu T; Rossolini GM; Marchese A; Ambretti S; Cauda R; Viscoli C; Lewis RE; Viale P; Tumbarello M; Int J Antimicrob Agents; 2018 Feb; 51(2):244-248. PubMed ID: 28842283 [TBL] [Abstract][Full Text] [Related]
16. Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary. Szilágyi E; Füzi M; Böröcz K; Kurcz A; Tóth A; Nagy K Acta Microbiol Immunol Hung; 2009 Sep; 56(3):251-62. PubMed ID: 19789140 [TBL] [Abstract][Full Text] [Related]
17. Epidemiological, clinical, and microbiological characteristics of carbapenemase-producing Enterobacteriaceae bloodstream infection in the Republic of Korea. Park JW; Lee H; Park SY; Kim TH Antimicrob Resist Infect Control; 2019; 8():48. PubMed ID: 30873279 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of cefepime breakpoint in patients with carbapenem-resistant Klebsiella pneumoniae bacteraemia. Lee NY; Lo CL; Chen PL; Syue LS; Li CW; Li MC; Ko WC Int J Antimicrob Agents; 2021 Feb; 57(2):106250. PubMed ID: 33264671 [TBL] [Abstract][Full Text] [Related]
19. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828 [TBL] [Abstract][Full Text] [Related]
20. External validation of the INCREMENT-CPE mortality score in a carbapenem-resistant Klebsiella pneumoniae bacteraemia cohort: the prognostic significance of colistin resistance. Machuca I; Gutiérrez-Gutiérrez B; Rivera-Espinar F; Cano A; Gracia-Ahufinger I; Guzman-Puche J; Marfil-Pérez E; Pérez-Nadales E; Castón JJ; Bonomo RA; Carmeli Y; Paterson D; Pascual Á; Martínez-Martínez L; Rodríguez-Baño J; Torre-Cisneros J; Int J Antimicrob Agents; 2019 Oct; 54(4):442-448. PubMed ID: 31377343 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]